Cited 0 times in
Stage 3 플러스 징후를 동반한 미숙아 망막병증에서 일차유리체강내 베바시주맙 주입술의 효과
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이승규 | - |
dc.contributor.author | 임형택 | - |
dc.contributor.author | 김성은 | - |
dc.date.accessioned | 2016-02-04T11:25:46Z | - |
dc.date.available | 2016-02-04T11:25:46Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 0378-6471 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/140404 | - |
dc.description.abstract | Purpose: To evaluate the efficacy and safety of primary intravitreal bevacizumab injection in stage 3 retinopathy of prematurity with plus signs. Methods: We reviewed retrospectively the medical records of 30 eyes of 16 patients diagnosed with stage 3 retinopathy of prematurity with plus signs treated with primary intravitreal bevacizumab injection between March 1, 2011 and February 28, 2013 and followed up for at least 9 months. Results: Mean gestational age was 26 + 4 weeks ± 11 days and mean birth weight was 822 ± 251.4 g. The locations of disease were zone II in 24 eyes and zone III in 6 eyes. Intravitreal bevacizumab injection was performed after the mean 1.3 ± 1 day after plus signs were detected. Mean postconceptional age at treatment was 38 + 2 weeks ± 16 days. Mean follow-up period was 16.6 ± 6.9 months. Plus signs started to regress after the mean 4.6 ± 2.3 days after injection and completely regressed after the mean 24.3 ± 12.4 days. Cataract extraction was performed in 1 eye due to a cataract that appeared not associated with the injection procedure, but was regarded as a treatment failure. There were no local or systemic complications. Conclusions: Primary intravitreal bevacizumab injection in stage 3 retinopathy of prematurity with plus signs demonstrated excellent short-term efficacy and safety. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.relation.isPartOf | JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Stage 3 플러스 징후를 동반한 미숙아 망막병증에서 일차유리체강내 베바시주맙 주입술의 효과 | - |
dc.title.alternative | Effect of Primary Intravitreal Bevacizumab Injection on Stage 3 Retinopathy of Prematurity with Plus Signs | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Ophthalmology (안과학) | - |
dc.contributor.googleauthor | 김성은 | - |
dc.contributor.googleauthor | 임형택 | - |
dc.contributor.googleauthor | 이승규 | - |
dc.identifier.doi | 10.3341/jkos.2015.56.1.62 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02913 | - |
dc.contributor.localId | A03419 | - |
dc.relation.journalcode | J01838 | - |
dc.identifier.eissn | 2092-9374 | - |
dc.subject.keyword | Avastin | - |
dc.subject.keyword | Bevacizumab | - |
dc.subject.keyword | Retinopathy of prematurity | - |
dc.contributor.alternativeName | Lee, Seung Kyu | - |
dc.contributor.alternativeName | Rim, Tyler H. T. | - |
dc.contributor.affiliatedAuthor | Lee, Seung Kyu | - |
dc.contributor.affiliatedAuthor | Rim, Tyler Hyungtaek | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 56 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 62 | - |
dc.citation.endPage | 69 | - |
dc.identifier.bibliographicCitation | JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, Vol.56(1) : 62-69, 2015 | - |
dc.identifier.rimsid | 51988 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.